Wall Street brokerages predict that Scpharmaceuticals Inc (NASDAQ:SCPH) will post ($0.50) earnings per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Scpharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.54) and the highest estimate coming in at ($0.45). Scpharmaceuticals posted earnings of ($0.53) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 5.7%. The business is scheduled to issue its next earnings report on Tuesday, August 13th.
According to Zacks, analysts expect that Scpharmaceuticals will report full-year earnings of ($2.02) per share for the current financial year, with EPS estimates ranging from ($2.13) to ($1.91). For the next year, analysts forecast that the firm will post earnings of ($1.39) per share, with EPS estimates ranging from ($1.46) to ($1.32). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research analysts that follow Scpharmaceuticals.
Scpharmaceuticals (NASDAQ:SCPH) last posted its earnings results on Wednesday, May 8th. The company reported ($0.47) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.52) by $0.05.
In other Scpharmaceuticals news, major shareholder Ra Capital Healthcare Fund Lp purchased 389,862 shares of the stock in a transaction dated Thursday, April 11th. The shares were acquired at an average cost of $2.70 per share, for a total transaction of $1,052,627.40. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 4.80% of the stock is owned by corporate insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. JPMorgan Chase & Co. boosted its position in Scpharmaceuticals by 1,268.6% during the third quarter. JPMorgan Chase & Co. now owns 22,664 shares of the company’s stock worth $133,000 after acquiring an additional 21,008 shares during the last quarter. BlackRock Inc. boosted its position in Scpharmaceuticals by 2.0% during the fourth quarter. BlackRock Inc. now owns 358,243 shares of the company’s stock worth $1,347,000 after acquiring an additional 7,094 shares during the last quarter. Jacobs Levy Equity Management Inc. acquired a new stake in Scpharmaceuticals during the first quarter worth approximately $71,000. Finally, SG Americas Securities LLC acquired a new stake in Scpharmaceuticals during the first quarter worth approximately $51,000. Hedge funds and other institutional investors own 42.33% of the company’s stock.
Shares of SCPH traded down $0.01 during trading hours on Wednesday, hitting $3.50. The stock had a trading volume of 2,200 shares, compared to its average volume of 91,587. The company has a debt-to-equity ratio of 0.10, a quick ratio of 8.50 and a current ratio of 8.50. Scpharmaceuticals has a 52 week low of $2.44 and a 52 week high of $15.00. The firm has a market cap of $63.92 million, a price-to-earnings ratio of -2.21 and a beta of 1.31.
Scpharmaceuticals Company Profile
scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is Furoscix that consists of proprietary subcutaneous formulation of furosemide, which is delivered through the SmartDose drug delivery system for treatment of congestion in decompensated heart failure patients outside of the acute care setting.
Read More: What is Net Asset Value (NAV)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Scpharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scpharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.